Skip to main content
. 2019 Apr 25;8(9):e011246. doi: 10.1161/JAHA.118.011246

Figure 2.

Figure 2

Trends in PCSK9 inhibitor prescriptions, July 2015 to March 2017. PCSK9 inhibitor prescription rates with 95% CIs during 6‐month intervals except the final reported time period (January–March 2017), which represents only 3 months. CAD indicates coronary artery disease; CHD, coronary heart disease; PCSK9, proprotein convertase subtilisin/kexin type 9.